On Thursday, Shares of MBIA Inc. (NYSE:MBI), lost -2.21% to $ 5.75.
MBIA Inc., declared that Thomas M. Metzold will join the company as Managing Director and Head of Capital Markets in early August. In this newly created position, Mr. Metzold will be responsible for leading National’s secondary markets business and for coordinating the firm’s outreach to buy and sell-side municipal bond trading desks. Mr. Metzold joins National following a 28-year career at Eaton Vance Administration, where he was a Senior Municipal Portfolio Advisor and portfolio manager for about $5.5 billion of municipal assets.
“We’re happy to welcome Tom to National,” said Tom Weyl, Managing Director and Head of New Business Development. “His extensive experience in the municipal bond market and deep understanding of the needs of traders, portfolio managers and credit analysts will be invaluable as we look to expand our secondary markets business and reestablish National’s leadership position in the bond insurance industry.”
MBIA Inc. provides financial guarantee insurance services to public finance markets in the United States and internationally. The company operates through U.S. Public Finance Insurance, and International and Structured Finance Insurance segments.
Shares of Teekay Tankers Ltd. (NYSE:TNK), inclined 2.94% to $7.18, during its last trading session.
Teekay Tankers Ltd., declared a cash dividend of $0.03 per share for the quarter ended June 30, 2015. The cash dividend is payable on July 31, 2015 to all shareholders of record as at July 17, 2015.
Teekay Tankers Ltd. is engaged in the marine transportation of crude oil and refined petroleum products through the operation of its oil and product tankers worldwide. As of December 31, 2014, it owned 27 double-hulled conventional oil tankers, time-chartered in 8 Aframax tankers, and 4 long range 2 product tankers from third parties; and owned a 50% interest in 1 very large crude carrier. The company was founded in 2007 and is headquartered in Hamilton, Bermuda.
Finally, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ended its last trade with 0.74% gained, and closed at $ 185.22.
Alexion Pharmaceuticals, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending marketing authorization of Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The projected indication for Strensiq is for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. The projected indication for Kanuma is for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-d). Based on the CHMP’s positive recommendations, final decisions from the European Commission are predictable in the third quarter of 2015, after which the Company will start the country-by-country reimbursement processes. Presently, there are no therapies approved for the treatment of HPP or LAL-d.
“The CHMP positive opinions for Strensiq and Kanuma are noteworthy milestones in bringing these therapies to infants, children, and adults suffering from HPP and LAL-d in Europe,” said David Hallal, Chief Executive Officer of Alexion. “Both Strensiq and Kanuma are highly innovative enzyme replacement therapies that, if approved, will be the first treatments accessible for patients with HPP and LAL-d, two life-threatening and ultra-rare metabolic disorders.”
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
